Table 3.

Comparison of estimated rate of change per year in clinical characteristics by treatment status, excluding subjects who initiated tafamidis treatment prior to enrollment in THAOS

Clinical outcome	Tafamidis (Est ± SE)	Matched controls (Est ± SE)	Tafamidis—matched controls (Est ± SE)	p value
Mapped NIS-LL	0.25 ± 0.56	2.80 ± 0.44	− 2.55 ± 0.50	< 0.001
NCS	0.51 ± 1.14	4.88 ± 0.84	− 4.37 ± 1.16	< 0.001
Reflex score	0.21 ± 0.06	0.19 ± 0.03	0.03 ± 0.07	0.71
Motor score	0.40 ± 0.46	2.47 ± 0.33	− 2.07 ± 0.44	< 0.001
Sensory score	0.20 ± 0.69	1.88 ± 0.46	− 1.67 ± 0.77	0.029
Norfolk TQoL score	− 2.75 ± 0.92	1.60 ± 0.54	− 4.35 ± 1.05	< 0.001
Karnofsky index	− 0.47 ± 0.34	0.18 ± 0.19	− 0.65 ± 0.38	0.085
mBMI, kg/m2 × g/L	20.54 ± 5.18	20.57 ± 3.13	− 0.03 ± 6.05	> 0.99
BUN, mg/dL	0.44 ± 0.85	3.27 ± 0.49	− 2.83 ± 0.98	0.004

Estimates were calculated from models of tafamidis treatment effect on outcome, adjusted for the baseline covariate

BUN blood urea nitrogen, Est estimate, mBMI modified body mass index, NCS Neurologic Composite Score, NIS-LL Neuropathy Impairment Score in the Lower Limbs, SE standard error, TQoL Total Quality of Life